Pharmacokinetics, Safety, and Tolerability of Rolapitant Administered Intravenously Following Single Ascending and Multiple Ascending Doses in Healthy Subjects-Reference-Cited by-同舟云学术

Pharmacokinetics, Safety, and Tolerability of Rolapitant Administered Intravenously Following Single Ascending and Multiple Ascending Doses in Healthy Subjects

Published:2018-06-15 Issue:2 Volume:8 Page:160-171
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Wang Xiaodong¹,Zhang Zhi‐Yi¹,Wang Jing¹,Powers Dan¹,Arora Sujata¹,Lu Sharon¹,Kansra Vikram¹

Affiliation:

1. Tesaro Inc. Waltham MA USA

Funder

Tesaro, Inc.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.580

Reference20 articles.

1. Multinational Association of Supportive Care in Cancer.MASCC/ESMO antiemetic guidelines 2016.http://www.mascc.org/assets/Guidelines-Tools/mascc_antiemetic_guidelines_english_v.1.2.1.pdf. Accessed May 18 2018.

2. National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology: antiemesis. Version 2.2018;https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed May 18 2018.

3. Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)

4. Long-Acting Serotonin Antagonist (Palonosetron) and the NK-1 Receptor Antagonists

5. Rolapitant (SCH 619734): A potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neurokinin-1 Receptor Antagonist Reverses Functional CNS Alteration Caused by Combined γ-rays and Carbon Nuclei Irradiation;CNS & Neurological Disorders - Drug Targets;2022-04

2. Neurokinin‐1 receptor antagonist rolapitant suppresses anxiety and alcohol intake produced by repeated withdrawal episodes;The FEBS Journal;2022-02-27

3. Oral Complications of Head and Neck Cancer Therapy;Forum of Clinical Oncology;2021-05-01

4. Population Pharmacokinetics of Rolapitant in Patients With Chemotherapy‐Induced Nausea and Vomiting;Clinical Pharmacology in Drug Development;2019-10

5. Neurokinin-1 receptor antagonists: review of their role for the prevention of chemotherapy-induced nausea and vomiting in adults;Expert Review of Clinical Pharmacology;2019-06-13